ArticleCureus2026
Utility of Serum Homocysteine and Lipoprotein(a) in Acute Coronary Syndrome: A Cross-Sectional Study From Western India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute coronary syndrome (ACS) remains a major cause of cardiovascular morbidity and mortality in India, with disease onset occurring at younger ages than in Western populations. Serum homocysteine and lipoprotein(a) Lp(a) are recognized non-conventional risk factors whose interrelationship and age-specific relevance in Indian patients with ACS remain poorly defined.
methodsThis cross-sectional study was undertaken at Dr. Sampurnanand Medical College and Mathura Das Mathur Hospital, Jodhpur, between January and November 2023. Seventy-five consecutive ACS patients (ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina) were enrolled. Serum homocysteine and Lp(a) were measured by immunoturbidimetry, with Lp(a) ≥30 mg/dL defined as elevated. Receiver operating characteristic (ROC) curve analysis was performed to identify the optimal homocysteine threshold for predicting young-onset ACS.
resultsYounger patients (aged below 40 years) demonstrated significantly higher homocysteine levels than older counterparts (p=0.0009). Elevated Lp(a) was present in nearly half the cohort and was accompanied by significantly higher homocysteine concentrations (p<0.0001). Vitamin B12 deficiency was identified in over half of the patients, potentially contributing to hyperhomocysteinaemia.
conclusionSerum homocysteine is markedly elevated in young-onset ACS and correlates positively with Lp(a) levels. These findings suggest that screening for both biomarkers, alongside vitamin B12 assessment, may warrant consideration in the workup of ACS patients, particularly in the Indian population. However, given the cross-sectional, single-center design of the present study and the absence of outcome data, prospective multicenter studies are needed to validate these associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.